Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

ISSN： 0114-5916

Source： Drug Safety, Vol.33, Iss.2, 2010-02, pp. : 87-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus

By Howlett H.C.S.

Drug Safety, Vol. 20, Iss. 6, 1999-06 ,pp. : 489-503

Adis International

Access to resources Recommend Favorite

Exenatide enhances standard therapy in type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1445, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Exenatide once weekly in type 2 diabetes mellitus

By Bischoff Lindsay A Jabbour Serge A Miller Jeffrey L

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1297-1303

Informa Healthcare

Access to resources Recommend Favorite

Hormone Replacement Therapy in Postmenopausal Women With Diabetes Mellitus: A Risk-Benefit Assessment

By Andersson B.

Drugs & Aging, Vol. 17, Iss. 5, 2000-11 ,pp. : 399-410

Adis International

Access to resources Recommend Favorite

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

By Briones Mariele Bajaj Mandeep

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite